AN2 Therapeutics (ANTX)
(Delayed Data from NSDQ)
$1.08 USD
0.00 (0.00%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $1.10 +0.02 (1.85%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, AN2 Therapeutics, Inc. has a market cap of $32.59M, which represents its share price of $1.08 multiplied by its outstanding shares number of 30.18M. As a small-cap company, ANTX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ANTX 1.08 0.00(0.00%)
Will ANTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANTX
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
ANTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ANTX
ANTX: AN2 Therapeutics Partners on Chagas Disease Oral Treatment | ANTX Stock News
AN2 Therapeutics, DNDi collaborate on development of AN2-502998
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to ...
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute ...
AN2 Therapeutics completes 200-patient observational study in acute melioidosis